AC Immune Parkinson’s Vaccine Study Meets Safety, Immunogenicity Goals
Published . Updated .
AC Immune (NASDAQ:ACIU) reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy designed to target aggregated alpha-synuclein in early Parkinson’s disease. The placebo-controlled study enrolled 34 participants, with 25 receiving
Directly affected
Indirectly affected
- SPY SPDR S&P 500+1.6%
The broad U.S. stock market
- TLT iShares 20+ Year Treasury Bond-1.8%
Long-term U.S. government bonds
- QQQ Invesco QQQ+2.3%
Large technology stocks
- GLD SPDR Gold Shares-3.3%
Gold can move with the broad market
Price reaction, T-5 to T+3
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
AC Immune (NASDAQ:ACIU) reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy designed to target aggregated alpha-synuclein in early Parkinson’s disease. The placebo-controlled study enr…
Source: Nasdaq Markets
Taiwan Strait
Taiwan Strait
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Where this story sits: Taiwan Strait
Taiwan Strait has 49 linked stories in the last 7 days and 49 in the last 30 on the page that also carries “AC Immune Parkinson’s Vaccine Study Meets Safety, Immunogenicity Goals.” The recent pace is rising.
Taiwan Strait
12 out of 100
“AC Immune Parkinson’s Vaccine Study Meets Safety, Immunogenicity Goals” scores 12 out of 100. The score uses 1 sources.